Labetuzumab anti-DTPA-indium bispecific monoclonal antibody

Drug Profile

Labetuzumab anti-DTPA-indium bispecific monoclonal antibody

Latest Information Update: 16 Apr 2004

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Recombinant fusion proteins
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamic sections
  • 24 Nov 2003 Data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2003) have been added to the Cancer pharmacodynamics section
  • 14 Aug 2003 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top